Literature DB >> 20707698

Rethinking prevention of HIV type 1 infection.

David N Burns1, Carl W Dieffenbach, Sten H Vermund.   

Abstract

Research on the prevention of human immunodeficiency virus (HIV)-1 infection is at a critical juncture. Major methodological challenges to performing prevention trials have emerged, and one after another promising biomedical interventions have failed to reduce the incidence of HIV-1 infection. Nevertheless, there is growing optimism that progress can be achieved in the near term. Mathematical modeling indicates that 2 new strategies, "test and treat" and preexposure prophylaxis, could have a major impact on the incidence of HIV-1 infection. Will our hopes be justified? We review the potential strengths and limitations of these antiretroviral "treatment as prevention" strategies and outline other new options for reducing the incidence of HIV-1 infection in the near term. By maximizing the potential of existing interventions, developing other effective strategies, and combining them in an optimal manner, we have the opportunity to bring the HIV-1 epidemic under control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20707698      PMCID: PMC3071685          DOI: 10.1086/655889

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  54 in total

Review 1.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

Authors:  J X Velasco-Hernandez; H B Gershengorn; S M Blower
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

Review 3.  Risk compensation: the Achilles' heel of innovations in HIV prevention?

Authors:  Michael M Cassell; Daniel T Halperin; James D Shelton; David Stanton
Journal:  BMJ       Date:  2006-03-11

4.  Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.

Authors:  S Foster; P Godfrey-Faussett; J Porter
Journal:  AIDS       Date:  1997-06       Impact factor: 4.177

5.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

6.  Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.

Authors:  Peter J Dodd; Geoff P Garnett; Timothy B Hallett
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

7.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  Stephanie Skoler-Karpoff; Gita Ramjee; Khatija Ahmed; Lydia Altini; Marlena Gehret Plagianos; Barbara Friedland; Sumen Govender; Alana De Kock; Nazira Cassim; Thesla Palanee; Gregory Dozier; Robin Maguire; Pekka Lahteenmaki
Journal:  Lancet       Date:  2008-12-06       Impact factor: 79.321

8.  HIV-prevention science at a crossroads: advances in reducing sexual risk.

Authors:  Sten H Vermund; Katherine L Allen; Quarraisha Abdool Karim
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

9.  HIV prevalence estimates--United States, 2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-10-03       Impact factor: 17.586

10.  Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

Authors:  Awewura Kwara; Allison Delong; Naser Rezk; Joseph Hogan; Heather Burtwell; Stacy Chapman; Carla C Moreira; Jaclyn Kurpewski; Jessica Ingersoll; Angela M Caliendo; Angela Kashuba; Susan Cu-Uvin
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

View more
  55 in total

1.  Beyond the distinction between biomedical and social dimensions of HIV prevention through the lens of a social public health.

Authors:  Susan Kippax; Niamh Stephenson
Journal:  Am J Public Health       Date:  2012-05       Impact factor: 9.308

2.  Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection.

Authors:  Patricia Sweeney; Lytt I Gardner; Kate Buchacz; Pamela Morse Garland; Michael J Mugavero; Jeffrey T Bosshart; R Luke Shouse; Jeanne Bertolli
Journal:  Milbank Q       Date:  2013-07-08       Impact factor: 4.911

3.  Preserving human rights in the era of "test and treat" for HIV prevention.

Authors:  Jeannia J Fu; Alexander R Bazazi; Frederick L Altice
Journal:  Am J Public Health       Date:  2011-02       Impact factor: 9.308

4.  HIV stigma as a barrier to retention in HIV care at a general hospital in Lima, Peru: a case-control study.

Authors:  Carla Valenzuela; Cesar Ugarte-Gil; Jorge Paz; Juan Echevarria; Eduardo Gotuzzo; Sten H Vermund; Aaron M Kipp
Journal:  AIDS Behav       Date:  2015-02

5.  The Continuum of HIV Care in the Urban United States: Black Men Who Have Sex With Men (MSM) Are Less Likely Than White MSM to Receive Antiretroviral Therapy.

Authors:  Sten H Vermund
Journal:  J Infect Dis       Date:  2017-10-17       Impact factor: 5.226

6.  Reproductive care in human immunodeficiency virus serodiscordant couples with haemophilia.

Authors:  Isabella Garagiola; Mimosa Mortarino; Augusto E Semprini; Flora Peyvandi
Journal:  Blood Transfus       Date:  2012-09-13       Impact factor: 3.443

Review 7.  Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis.

Authors:  Connie Celum; Jared M Baeten
Journal:  Antivir Ther       Date:  2012-12-07

8.  Community viral load as a measure for assessment of HIV treatment as prevention.

Authors:  William C Miller; Kimberly A Powers; M Kumi Smith; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2013-03-25       Impact factor: 25.071

9.  Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.

Authors:  Vivek Jain; Teri Liegler; Jane Kabami; Gabriel Chamie; Tamara D Clark; Douglas Black; Elvin H Geng; Dalsone Kwarisiima; Joseph K Wong; Mohamed Abdel-Mohsen; Nitin Sonawane; Francesca T Aweeka; Harsha Thirumurthy; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Diane V Havlir
Journal:  Clin Infect Dis       Date:  2012-12-12       Impact factor: 9.079

10.  Improving Adherence to Care Among "Hard to Reach" HIV-Infected Patients in Argentina.

Authors:  Deborah L Jones; Omar Sued; Diego Cecchini; Lina Bofill; Ryan Cook; Mar Lucas; Alejandra Bordato; Isabel Cassetti; Pedro Cahn; Stephen M Weiss
Journal:  AIDS Behav       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.